408 documents

Read All
16:55 , Apr 19, 2019 |  BC Week In Review  |  Company News

BioSense gets Asia rights to Rexahn's pancreatic cancer therapy

BioSense gained exclusive rights to develop and commercialize Rexahn's RX-3117 to treat and prevent pancreatic cancer in Singapore, China, Hong Kong, Macau and Taiwan. Rexahn Pharmaceuticals Inc. (NYSE-A:RNN) will receive $3 million up front and...
Read More
18:46 , Apr 12, 2019 |  BC Week In Review  |  Company News

Sorrento sues NantWorks' Soon-Shiong over alleged 'catch and kill' scheme

Sorrento filed two lawsuits against Patrick Soon-Shiong and companies under his NantWorks umbrella for allegedly buying cancer therapy Cynviloq, a potential competitor to Abraxane nab-paclitaxel, through a "catch and kill" scheme to prevent it from...
Read More
22:23 , Apr 1, 2019 |  BC Extra  |  Clinical News

Roche's ipatasertib-Tecentriq combo leads to 73% ORR in TNBC patients

Roche plans to start a Phase III trial this year to evaluate a combination of ipatasertib plus PD-L1 inhibitor Tecentriq atezolizumab and paclitaxel as first-line treatment of metastatic triple-negative breast cancer following a Phase Ib...
Read More
13:53 , Apr 1, 2019 |  BC Extra  |  Clinical News

Apexigen's CD40 agonist shows response in pancreatic cancer

Over half of metastatic pancreatic cancer patients treated with Apexigen's APX005M as part of a combination regimen that included Opdivo nivolumab had a response, suggesting that the combination along with SOC could provide a new...
Read More
17:57 , Mar 22, 2019 |  BC Week In Review  |  Company News

EC approves Keytruda for first-line NSCLC regardless of PD-L1 expression

Merck & Co. said the European Commission approved Keytruda pembrolizumab plus carboplatin and either paclitaxel or Abraxane nab-paclitaxel as first-line treatment of metastatic, squamous non-small cell lung cancer regardless of PD-L1 expression. Merck & Co....
Read More
06:09 , Mar 19, 2019 |  BC Extra  |  Company News

Tecentriq first front-line extensive-stage SCLC therapy in decades

FDA's approval late Monday of Roche's Tecentriq atezolizumab as front-line treatment for extensive-stage small cell lung cancer marks the first approval of a PD-1/PD-L1 inhibitor in the indication. The drug is also the first initial...
Read More
22:01 , Mar 15, 2019 |  BioCentury  |  Product Development

Broadening the PARP playing field

With its latest clinical win for Lynparza, AstraZeneca is leading the field in stretching the use of PARP inhibitors beyond tumors that carry BRCA mutations. The results highlight one piece of a broader strategy companies...
Read More
17:34 , Mar 15, 2019 |  BC Week In Review  |  Clinical News

Abraxane as adjuvant misses primary in resected pancreatic cancer

Celgene said Abraxane nab-paclitaxel plus gemcitabine missed the primary endpoint of improving disease-free survival vs. gemcitabine alone in the Phase III apact trial evaluating the drugs as adjuvant therapy for patients with surgically resected pancreatic...
Read More
18:42 , Mar 8, 2019 |  BC Extra  |  Company News

TNBC gets its first targeted agent with Tecentriq approval

The approval of Roche's Tecentriq atezolizumab to treat metastatic triple-negative breast cancer gives almost half of these patients and physicians' their first agent to treat a molecularly defined subgroup of patients with this fast-progressing cancer....
Read More
01:42 , Mar 1, 2019 |  BC Week In Review  |  Company News

Celgene products drive BeiGene 4Q revenue gains

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) reported its 4Q18 earnings late Feb. 27 with revenue gains driven by its in-licensed products from Celgene Corp. (NASDAQ:CELG). BeiGene's portfolio includes Chinese rights to cancer drugs Abraxane nab-paclitaxel, Revlimid lenalidomide...
Read More